These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 30802149)

  • 1. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
    Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
    Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Gastroenterology; 2024 Jul; 167(2):264-280. PubMed ID: 38417530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy.
    Jiang K; Li J; Zhang J; Wang L; Zhang Q; Ge J; Guo Y; Wang B; Huang Y; Yang T; Hao D; Shan L
    Int Immunopharmacol; 2019 Oct; 75():105818. PubMed ID: 31437795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression.
    Li B; Zeng Y; Reeves PM; Ran C; Liu Q; Qu X; Liang Y; Liu Z; Yuan J; Leblanc PR; Ye Z; Sluder AE; Gelfand JA; Brauns TA; Chen H; Poznansky MC
    Cancer Immunol Res; 2018 May; 6(5):539-551. PubMed ID: 29511032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
    Xue J; Li R; Gao D; Chen F; Xie H
    Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
    Duraiswamy J; Freeman GJ; Coukos G
    Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.
    Biasci D; Smoragiewicz M; Connell CM; Wang Z; Gao Y; Thaventhiran JED; Basu B; Magiera L; Johnson TI; Bax L; Gopinathan A; Isherwood C; Gallagher FA; Pawula M; Hudecova I; Gale D; Rosenfeld N; Barmpounakis P; Popa EC; Brais R; Godfrey E; Mir F; Richards FM; Fearon DT; Janowitz T; Jodrell DI
    Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28960-28970. PubMed ID: 33127761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CXCR4/CXCL12 axis via [
    Bao G; Wang Z; Liu L; Zhang B; Song S; Wang D; Cheng S; Moon ES; Roesch F; Zhao J; Yu B; Zhu X
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2744-2757. PubMed ID: 38587644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
    Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
    Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
    Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
    J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
    Liu Y; Ren CC; Yang L; Xu YM; Chen YN
    J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
    Feig C; Jones JO; Kraman M; Wells RJ; Deonarine A; Chan DS; Connell CM; Roberts EW; Zhao Q; Caballero OL; Teichmann SA; Janowitz T; Jodrell DI; Tuveson DA; Fearon DT
    Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20212-7. PubMed ID: 24277834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer.
    Lu G; Qiu Y; Su X
    Eur J Pharm Sci; 2021 Feb; 157():105606. PubMed ID: 33131745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
    Gil M; Komorowski MP; Seshadri M; Rokita H; McGray AJ; Opyrchal M; Odunsi KO; Kozbor D
    J Immunol; 2014 Nov; 193(10):5327-37. PubMed ID: 25320277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.
    Righi E; Kashiwagi S; Yuan J; Santosuosso M; Leblanc P; Ingraham R; Forbes B; Edelblute B; Collette B; Xing D; Kowalski M; Mingari MC; Vianello F; Birrer M; Orsulic S; Dranoff G; Poznansky MC
    Cancer Res; 2011 Aug; 71(16):5522-5534. PubMed ID: 21742774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.